FDA asks infant formula makers to strengthen safeguards after botulism

On July 13, 2026, the U.S. Food and Drug Administration (FDA) sent a letter to the infant formula industry urging stronger safeguards—especially around supplier oversight—after FDA-linked investigations involving infant botulism illnesses associated with powdered infant formula.

At the same time, CDC’s guidance continues to emphasize a practical message for caregivers: powdered infant formula is not sterile, and preparation/storage choices matter—particularly for higher-risk babies.

What changed on July 13: FDA’s letter to the industry

In a July 13 constituent update, FDA said it asked infant formula makers to increase vigilance and strengthen how they manage risk that could enter through the supply chain. FDA framed the expectation in “know your suppliers” terms—understanding where ingredients come from, how they’re produced, and whether supplier-related risks are effectively controlled.

FDA says the work is shifting from response to prevention

FDA’s separate post-outbreak response page says the agency has moved beyond initial outbreak response into post-response prevention activities. Those actions include ongoing root-cause work, continued surveillance/sampling, and steps meant to reduce the chance of similar problems recurring. FDA also notes that investigations connected to multiple inquiries are ongoing, and that the agency is still working to understand contributing factors.

What infant botulism is—and why timing matters

CDC describes infant botulism as a rare but serious illness that can happen when an infant swallows Clostridium botulinum spores. In the gut, the spores can lead to production of botulinum neurotoxin, which can interfere with normal body functions.

CDC emphasizes that clinical suspicion matters: treatment should not wait for lab confirmation when a clinician suspects infant botulism.

Early symptoms caregivers may notice can include:

• Constipation
• Poor feeding or reduced appetite
• Drooping eyelids and/or weak facial expression
• Weak suck and/or diminished reflexes (like gagging)
• Changes in cry (weak or altered)
• Breathing problems or respiratory pauses

If you notice concerning symptoms—especially in a very young infant—seek urgent medical care and tell clinicians you’re concerned about possible infant botulism.

Powdered formula prep: CDC’s safer steps for caregivers

CDC warns that powdered infant formula is not sterile. CDC provides preparation and storage guidance for all caregivers using powdered formula, with extra precautions for babies at higher risk.

CDC’s core approach includes:

• Boil water, then follow CDC’s guidance on how long to cool it before mixing.
• Mix the powder with water at the temperature/time CDC recommends to help prevent burns and support safer preparation.
• Check feeding temperature before giving formula and follow manufacturer instructions for handling and storage.

Important: CDC’s preparation guidance is designed to reduce risk from germs that may be present in powdered formula. It is not a guarantee against infant botulism, which is why symptom awareness and urgent care still matter.

Extra precautions for younger, premature, or immunocompromised infants

CDC says caregivers should take additional care when preparing powdered formula for babies who are younger than 2 months, were born prematurely (before 37 weeks), or have a weakened immune system. CDC’s added emphasis focuses on careful water handling and ensuring the formula is prepared at the temperature CDC recommends before feeding.

If water safety is an issue

CDC also addresses situations where tap water may be unsafe. In those cases, CDC advises using safer alternatives (such as bottled or ready-to-feed options) until local authorities confirm water is safe, and following public health directions.

What to watch next

FDA says it will continue updating its post-outbreak information as prevention and surveillance activities progress. For families, the practical takeaway is twofold: know the red flags for infant botulism and get urgent care if symptoms appear, and follow CDC’s powdered-formula preparation guidance—especially for the youngest, premature, or medically vulnerable infants.

Sources

• FDA: Post-response prevention actions (powdered infant formula–associated botulism investigations)
• CDC: Infant botulism clinical overview (treatment should not wait for lab confirmation)

Related News

• FDA revokes Orange B and proposes Citrus Red No. 2 revocation
• FDA: Cyclospora iceberg lettuce probe updates after false-positive result
• Groups Sue FDA Over Enforcement Guidance for Unauthorized Vapes, Nicotine Pouches
• GAO: Fraud-risk and improper-payment gaps persist in VA Community Care, Medicare Advantage